{"id":"W4402560725","doi":"10.1016/j.annonc.2024.08.1045","title":"985P Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; Ipsen; Sociedad Española de Oncología Médica; Sierra Oncology; Fondation ARC pour la Recherche sur le Cancer; Pfizer; Incyte; NuCana; Moderna; BeiGene; Seagen; Pharmacyclics; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Institut National Du Cancer; AstraZeneca; Novocure; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Astellas Pharma; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; PharmaMar; European Society for Medical Oncology; OncoMed Pharmaceutical; Celgene","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002437421,0.0006643805,0.0009377943,0.0003541186,0.0003316076,0.001059939,0.0007500073,0.0009837544,0.005419032],"category_scores_gemma":[0.002162714,0.0004059393,0.001903876,0.0004805115,0.000552495,0.0004688402,0.0003783487,0.001661843,0.00103806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001059555,"about_ca_system_score_gemma":0.001305079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001173746,"about_ca_topic_score_gemma":0.002139873,"domain_scores_codex":[0.9989612,0.0005561851,0.00004836795,0.0001569268,0.0001503001,0.0001270667],"domain_scores_gemma":[0.998833,0.0002798222,0.0002597544,0.0001267679,0.0001471865,0.0003534398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7033443,0.003624682,0.05592173,0.0008719462,0.006414392,0.000413413,0.0001083289,0.001845872,0.0330959,0.001173202,0.03365041,0.1595359],"study_design_scores_gemma":[0.6106411,0.1654924,0.151506,0.0002041088,0.007876918,0.001732225,0.00009669288,0.003371688,0.01513868,0.001704068,0.0421544,0.00008186122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9641238,0.005869658,0.001696964,0.003336374,0.0005884267,0.001356367,0.01389163,0.0002579398,0.00887874],"genre_scores_gemma":[0.9754624,0.00128939,0.002400155,0.001985118,0.0003338779,0.0006313742,0.01430973,0.000087277,0.003500591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005419032,"threshold_uncertainty_score":0.01812851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1170018200968944,"score_gpt":0.3852819610117513,"score_spread":0.2682801409148569,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}